Want to see MDGL full AI Analyst Report?
Madrigal Pharmaceuticals (MDGL) Ratios
Madrigal Pharmaceuticals Ratios
MDGL's free cash flow for Q2 2026 was $19.08M. For the 2026 fiscal year, MDGL's free cash flow was decreased by $-4.25M and operating cash flow was $23.33M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.01 | 6.10 | 5.38 | 3.12 | 3.54 |
| Quick Ratio | 3.77 | 5.90 | 5.38 | 3.12 | 3.54 |
| Cash Ratio | 0.64 | 0.59 | 0.84 | 2.86 | 0.47 |
| Solvency Ratio | -0.44 | -1.61 | -1.59 | -1.79 | -3.13 |
| Operating Cash Flow Ratio | -0.61 | -2.69 | -2.74 | -1.94 | -2.39 |
| Short-Term Operating Cash Flow Coverage | -186.20 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 588.87M | $ 745.06M | $ 402.07M | $ 196.19M | $ 194.46M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.28 | 0.11 | 0.18 | 0.14 | 0.00 |
| Debt-to-Equity Ratio | 0.59 | 0.16 | 0.29 | 0.25 | 0.00 |
| Debt-to-Capital Ratio | 0.37 | 0.14 | 0.22 | 0.20 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.37 | 0.13 | 0.22 | 0.20 | 0.00 |
| Financial Leverage Ratio | 2.09 | 1.38 | 1.58 | 1.84 | 1.39 |
| Debt Service Coverage Ratio | -11.34 | -30.68 | -28.35 | -73.39 | 0.00 |
| Interest Coverage Ratio | -13.45 | -33.94 | -29.93 | -74.06 | 0.00 |
| Debt to Market Cap | 0.03 | 0.02 | 0.03 | 0.01 | 0.00 |
| Interest Debt Per Share | 16.79 | 6.31 | 6.95 | 3.14 | 0.05 |
| Net Debt to EBITDA | -0.59 | -0.04 | -0.05 | 0.97 | 0.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 94.14% | 96.54% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -27.75% | -250.49% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | -27.59% | -249.88% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -31.31% | -276.39% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | -30.08% | -258.64% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | -30.08% | -258.64% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -30.08% | -258.64% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 96.06% | 93.58% | 98.20% | 100.61% | 99.74% |
| Return on Assets (ROA) | -22.89% | -44.70% | -58.33% | -81.46% | -88.48% |
| Return on Equity (ROE) | -47.83% | -61.76% | -92.18% | -149.63% | -123.32% |
| Return on Capital Employed (ROCE) | -31.61% | -57.03% | -72.89% | -119.01% | -123.40% |
| Return on Invested Capital (ROIC) | -31.58% | -56.97% | -72.82% | -118.72% | -123.15% |
| Return on Tangible Assets | -23.02% | -44.90% | -58.33% | -81.46% | -88.48% |
| Earnings Yield | -2.21% | -7.10% | -8.64% | -5.94% | -17.26% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.13 | 3.35 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 1.15 | 0.14 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.75 | 0.18 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 148.87 | 39.24 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.76 | 0.17 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 1.07 | 0.26 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 219.99 | -449.07 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 51.21 | 109.06 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 486.52 | 1995.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 317.74 | 2553.13 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 537.73 | 2104.06 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -8.45 | -21.42 | -17.35 | -13.12 | -11.12 |
| Free Cash Flow Per Share | -8.47 | -21.48 | -17.43 | -13.13 | -11.14 |
| Dividend Paid and CapEx Coverage Ratio | -405.90 | -311.61 | -219.22 | -1036.21 | -879.99 |
| Capital Expenditure Coverage Ratio | -405.90 | -311.61 | -219.22 | -1036.21 | -879.99 |
| Operating Cash Flow Coverage Ratio | -0.53 | -3.81 | -2.77 | -4.51 | -230.76 |
| Operating Cash Flow to Sales Ratio | -0.20 | -2.53 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -1.45% | -6.96% | -7.53% | -4.52% | -13.14% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -45.32 | -14.09 | -11.57 | -16.84 | -5.79 |
| Price-to-Sales (P/S) Ratio | 13.63 | 36.44 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 21.68 | 8.70 | 10.67 | 25.20 | 7.15 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -68.75 | -14.36 | -13.28 | -22.10 | -7.61 |
| Price-to-Operating Cash Flow Ratio | -68.92 | -14.41 | -13.34 | -22.12 | -7.62 |
| Price-to-Earnings Growth (PEG) Ratio | 1.10 | -1.47 | -0.72 | -0.95 | -0.49 |
| Enterprise Value Multiple | -49.99 | -14.63 | -12.05 | -16.13 | -5.66 |
| Enterprise Value | 13.22B | 6.58B | 4.34B | 4.69B | 1.37B |
| EV to EBITDA | -49.99 | -14.63 | -12.05 | -16.13 | -5.66 |
| EV to Sales | 13.79 | 36.55 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -69.57 | -14.41 | -13.33 | -20.85 | -7.42 |
| EV to Operating Cash Flow | -69.74 | -14.45 | -13.39 | -20.87 | -7.43 |
| Tangible Book Value Per Share | 26.54 | 35.24 | 21.69 | 11.52 | 11.86 |
| Shareholders’ Equity Per Share | 26.86 | 35.46 | 21.69 | 11.52 | 11.86 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 42.72 | 8.47 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.08 | 1.03 | 1.04 | 1.01 | 1.00 |
| Research & Development to Revenue | 0.41 | 1.31 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.85 | 2.42 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.10 | 0.44 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.66 | 0.98 | 0.87 | 0.76 | 0.76 |
Currency in USD
